These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19739274)

  • 1. Cetuximab-associated pulmonary toxicity.
    Chua W; Peters M; Loneragan R; Clarke S
    Clin Colorectal Cancer; 2009 Apr; 8(2):118-20. PubMed ID: 19739274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
    de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
    Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papulopustular drug eruption due to an epidermal growth factor receptor inhibitors, erlotinib and cetuximab.
    Bragg J; Pomeranz MK
    Dermatol Online J; 2007 Jan; 13(1):1. PubMed ID: 17511934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
    Rodriguez NA; Ascaso FJ
    J Clin Oncol; 2011 Jun; 29(18):e532-3. PubMed ID: 21483009
    [No Abstract]   [Full Text] [Related]  

  • 6. Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer.
    Van Cutsem E
    Oncologist; 2006 Oct; 11(9):1010-7. PubMed ID: 17030643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular toxicity related to cetuximab monotherapy in an advanced colorectal cancer patient.
    Tonini G; Vincenzi B; Santini D; Olzi D; Lambiase A; Bonini S
    J Natl Cancer Inst; 2005 Apr; 97(8):606-7. PubMed ID: 15840884
    [No Abstract]   [Full Text] [Related]  

  • 8. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody).
    Foerster CG; Cursiefen C; Kruse FE
    Cornea; 2008 Jun; 27(5):612-4. PubMed ID: 18520515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.
    Heun J; Holen K
    Clin Colorectal Cancer; 2007 May; 6(7):529-31. PubMed ID: 17553202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
    Sastre J; Aranda E; Grávalos C; Massutí B; Varella-Garcia M; Rivera F; Soler G; Carrato A; Manzano JL; Díaz-Rubio E; Hidalgo M
    Crit Rev Oncol Hematol; 2011 Jan; 77(1):78-84. PubMed ID: 20042346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing cetuximab hypersensitivity-infusion reactions: incidence, risk factors, prevention, and retreatment.
    George TJ; Laplant KD; Walden EO; Davis AB; Riggs CE; Close JL; George SN; Lynch JW
    J Support Oncol; 2010; 8(2):72-7. PubMed ID: 20464886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
    Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab for the treatment of colorectal cancer.
    Jonker DJ; O'Callaghan CJ; Karapetis CS; Zalcberg JR; Tu D; Au HJ; Berry SR; Krahn M; Price T; Simes RJ; Tebbutt NC; van Hazel G; Wierzbicki R; Langer C; Moore MJ
    N Engl J Med; 2007 Nov; 357(20):2040-8. PubMed ID: 18003960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe acneiform eruption induced by cetuximab (Erbitux).
    Lee JE; Lee SJ; Lee HJ; Lee JH; Lee KH
    Yonsei Med J; 2008 Oct; 49(5):851-2. PubMed ID: 18972607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First- and second-line therapy of metastatic colorectal cancer.
    Terstriep S; Grothey A
    Expert Rev Anticancer Ther; 2006 Jun; 6(6):921-30. PubMed ID: 16761936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trichomegaly of the eyelashes after colorectal cancer treatment with the epidermal growth factor receptor inhibitor cetuximab.
    Bambury R; McCaffrey JA
    Clin Colorectal Cancer; 2009 Oct; 8(4):235. PubMed ID: 19822516
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
    D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.